Ph.D., President and CEO
Dr. Julie M. Cherrington, Ph.D. Dr. Julie M. Cherrington, Ph.D. is a life science executive with extensive experience bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA approved products, including SUTENT™, Palladia™, Vistide™, Viread™, and Hepsera™.
Julie currently serves as President and CEO of Arch Oncology, an immuno-oncology company. Most recently, Julie served as President and CEO of Revitope, also an immune-oncology company and before that was President and CEO of Zenith Epigenetics, a bromodomain inhibitor company. From 2009 to 2014, Julie was President and CEO of Pathway Therapeutics, a clinical stage company advancing targeted kinase inhibitors. Prior to joining Pathway, she served as President and EVP of R&D of Phenomix Corporation. Prior to joining Phenomix in 2003, Julie was vice president of preclinical and clinical research at SUGEN, a Pharmacia/Pfizer company. Julie began her career at Gilead Sciences where she held a range of positions of increasing responsibility.
She has served on the Boards of Directors of Chemgenex, Progen and Xenome. She is currently a member of the Scientific Advisory Board of the Clearity Foundation and is an advisor in entrepreneurship initiatives at the California Life Sciences Institute (CLSI),
UC San Francisco, and UC Davis.
Dr. McKearn, Ph.D. joined RiverVest in April 2008 as a Venture Partner and became a Managing Director in April 2011. He has over 25 years of experience as a successful “drug hunter and developer” in both large and small biopharma, including a decade in small-cap and venture-backed companies. John serves on the board of Otonomy Inc., Lumena Pharmaceuticals, Inc., Allakos and ZS Pharma, all RiverVest Fund II portfolio companies. Prior to joining RiverVest, he was president and CEO of Kalypsys, Inc., and has served on the boards of IDM Pharma, Inc. (acquired by Takeda), Epimmune and Keel Pharmaceuticals, Inc. John holds more than 50 patents and numerous patent applications, primarily in the areas of cancer treatment and inflammatory disease. John worked as a scientist with Searle / Pharmacia, from 1987-2003, including head of discovery research from 1997-2003. Through his efforts, John helped establish the groundwork for new studies that led to the commercialization of several major products, including DayPro, Arthrotec, and most notably, Celebrex, one of the leading pharmaceuticals to treat arthritis.
Prior to 1987, John was a senior scientist at E.I. DuPont de Nemours and Company; a member of the Basel Institute for Immunology in Basel, Switzerland; and a research associate in the Department of Microbiology and Immunology at Washington University in St. Louis. Additionally, he has co-authored more than 70 published, peer-reviewed scientific papers. John completed his Ph.D. in immunology from the University of Chicago and his B.S. in biology from Northern Illinois University.
Carole Nuechterlein joined F. Hoffmann-La Roche Ltd. in 2002 and currently serves as a deputy director and head of the Roche Venture Fund. Prior to that, Ms. Nuechterlein served as general counsel for SangStat, Inc.
She currently serves on the board of directors for AveXis Inc and Lysosomal Therapeutics Inc and as an observer at Allakos and Epic Sciences. Ms. Nuechterlein holds a B.A. from Valparaiso University and a J.D. from University of Michigan.